Incidence and HR of cholelithiasis compared between non-HT cohort and patients with HT with and without thyroxine (T4) treatment
| Variables | n | Event | Person-years | Rate† | Crude HR | Adjusted HR‡ (95% CI) |
| (95% CI) | ||||||
| Non-HT controls | 5021 | 66 | 29 508 | 2.24 | 1 (reference) | 1 (reference) |
| HT without T4 treatment | 556 | 12 | 3276 | 3.66 | 1.64 (1.29 to 2.09)*** | 1.95 (1.53 to 2.49)*** |
| HT with T4 treatment | 712 | 16 | 4213 | 3.8 | 1.70 (1.37 to 2.10)*** | 1.94 (1.51 to 2.49)*** |
Crude HR, relative HR.
*P<0.05, **p<0.01, ***p<0.001.
†Incidence rate, per 1000 person-years.
‡Adjusted HR: multivariable analysis including age, sex, and comorbidities of hyperlipidaemia, diabetes, liver cirrhosis, hypertension, chronic obstructive pulmonary disease, coronary artery disease, inflammatory bowel disease, hyperthyroidism and hypothyroidism.
HT, Hashimoto’s thyroiditis.